What Is Semax?

Semax is a synthetic peptide of seven residues that traces back to a short fragment of adrenocorticotropic hormone, ACTH. It is studied in neuropeptide research, the field concerned with short peptide signals and the receptors they reach. This profile sets out the molecule, its origin in an ACTH fragment, and the research it appears in, and makes no statement about use.

Semax is related to ACTH(4-10), a fragment of the larger hormone, with a Pro-Gly-Pro extension added at one end. That extension is the design feature that distinguishes it: it slows the enzymes that would otherwise break the short sequence down, giving a more stable research peptide. Semax came out of neuropeptide research programmes, and the synthetic route behind peptides of this kind is in how peptides are manufactured.

ACTH itself is a longer signalling hormone, and its short fragments have been a subject of neuropeptide research for some time. Semax sits in that line of work, taking the ACTH(4-10) region and adding the terminal Pro-Gly-Pro extension, and it is one of the more frequently cited members of the fragment-derived neuropeptide group in that literature. Much of the early work originated in specific national research traditions, which is part of why reading the literature rewards attention to where and how each study was done.

As a heptapeptide, Semax is seven residues, combining the ACTH(4-10)-related core with the stabilising terminal addition. Short and water-soluble, it is handled as a lyophilised powder, as listed on the Semax product page; the general idea of what a peptide is sits in what is a peptide?

Semax is of interest as a stable, short neuropeptide derived from a natural hormone fragment, which makes it a tractable subject for studying how such fragments behave. Its terminal extension also serves as a clear example of stabilising a peptide by design, a theme that recurs across research peptides. The factual, claim-free framing this category requires is set out in our note on understanding research compounds.

Published work places Semax in neuropeptide research, examining the molecule as a stable ACTH-fragment analogue and characterising its properties in laboratory systems. These describe the peptide in research settings, with no implication about use. Other compounds studied in cognitive and signalling research contexts appear in the research catalogue.

A distinguishing thread in this work is the comparison between the bare ACTH(4-10) region and the extended Semax sequence, since setting the two side by side is what reveals what the stabilising addition changes. Studies of this kind treat Semax as a defined, reproducible subject and keep their conclusions tied to the molecule itself rather than to the parent hormone it derives from.

Much of the Semax literature originates in neuropeptide research traditions, and reading it calls for care to keep observations tied to their studies. The Semax research overview takes up the investigated areas and the limits of the evidence.

All products are supplied strictly for laboratory research use only. Not for human or animal consumption. Not a drug, supplement, or food. Not for diagnostic or therapeutic use. The material on this page is educational and factual: it summarises areas of published scientific investigation and general laboratory practice. It is not guidance for the use of any material in humans or animals, and nothing here should be read as a claim about safety, performance, or outcomes. Where a specific product specification or safety data sheet is provided with a material, that document is the definitive reference and takes precedence over any general information given here.